188.97
-7.86 (-3.99%)
| Previous Close | 196.83 |
| Open | 194.90 |
| Volume | 1,815,889 |
| Avg. Volume (3M) | 1,054,023 |
| Market Cap | 11,482,783,744 |
| Price / Earnings (Forward) | 7.79 |
| Price / Sales | 2.60 |
| Price / Book | 2.59 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Profit Margin | 11.86% |
| Operating Margin (TTM) | -2.90% |
| Diluted EPS (TTM) | 7.37 |
| Quarterly Revenue Growth (YOY) | -0.50% |
| Quarterly Earnings Growth (YOY) | 103.00% |
| Total Debt/Equity (MRQ) | 129.82% |
| Current Ratio (MRQ) | 3.38 |
| Operating Cash Flow (TTM) | 1.56 B |
| Levered Free Cash Flow (TTM) | 1.50 B |
| Return on Assets (TTM) | 3.99% |
| Return on Equity (TTM) | 12.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Jazz Pharmaceuticals plc | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 2.0 |
| Average | 2.38 |
|
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.04% |
| % Held by Institutions | 101.22% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 275.00 (B of A Securities, 45.53%) | Buy |
| Median | 230.00 (21.71%) | |
| Low | 195.00 (RBC Capital, 3.19%) | Buy |
| Average | 233.57 (23.60%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 186.39 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 27 Feb 2026 | 224.00 (18.54%) | Buy | 190.02 |
| B of A Securities | 25 Feb 2026 | 275.00 (45.53%) | Buy | 196.83 |
| Morgan Stanley | 25 Feb 2026 | 226.00 (19.60%) | Buy | 196.83 |
| RBC Capital | 25 Feb 2026 | 195.00 (3.19%) | Buy | 196.83 |
| Wells Fargo | 25 Feb 2026 | 250.00 (32.30%) | Buy | 196.83 |
| Needham | 12 Jan 2026 | 235.00 (24.36%) | Buy | 163.68 |
| Truist Securities | 12 Jan 2026 | 230.00 (21.71%) | Buy | 163.68 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Jan 2026 | Announcement | Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer |
| 06 Jan 2026 | Announcement | Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |